- Report
- September 2025
- 80 Pages
United Kingdom
From €4248EUR$4,850USD£3,687GBP
- Report
- September 2025
- 82 Pages
Germany
From €4248EUR$4,850USD£3,687GBP
- Report
- September 2025
- 91 Pages
Poland
From €4248EUR$4,850USD£3,687GBP
- Report
- September 2025
- 96 Pages
Germany
From €4248EUR$4,850USD£3,687GBP
- Book
- September 2025
- 488 Pages
From €350EUR$400USD£304GBP
- Report
- August 2025
- 80 Pages
From €3022EUR$3,450USD£2,623GBP
- Report
- June 2025
- 80 Pages
From €3022EUR$3,450USD£2,623GBP
- Report
- June 2025
- 75 Pages
France
From €2146EUR$2,450USD£1,862GBP
- Training
- December 2024
- 3 Days
Global
From €2041EUR$2,331USD£1,772GBP
- Report
- October 2024
- 70 Pages
North America
From €832EUR$950USD£722GBP
- Report
- October 2024
- 70 Pages
Asia Pacific
From €832EUR$950USD£722GBP
- Report
- October 2024
- 70 Pages
Latin America
From €832EUR$950USD£722GBP
- Report
- October 2024
- 70 Pages
China
From €832EUR$950USD£722GBP
- Report
- October 2024
- 70 Pages
France
From €832EUR$950USD£722GBP
- Report
- October 2024
- 70 Pages
Germany
From €832EUR$950USD£722GBP
- Report
- October 2024
- 70 Pages
India
From €832EUR$950USD£722GBP
- Report
- October 2024
- 70 Pages
United States
From €832EUR$950USD£722GBP
- Report
- September 2024
- 97 Pages
Global
From €4248EUR$4,850USD£3,687GBP
- Report
- September 2024
- 117 Pages
Global
From €3941EUR$4,500USD£3,421GBP
- Report
- September 2024
- 115 Pages
Global
From €3941EUR$4,500USD£3,421GBP

The biologic market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs. Biologic drugs are made from living organisms, such as proteins, nucleic acids, and cells, and are used to treat a variety of diseases. These drugs are typically more complex and expensive to produce than traditional small-molecule drugs. The biologic market is highly competitive, with many companies vying for market share.
The biologic market is divided into two main segments: therapeutic biologics and biosimilars. Therapeutic biologics are drugs that are developed to treat a specific disease or condition, while biosimilars are drugs that are similar to existing biologic drugs but are not identical.
Some of the major players in the biologic market include Amgen, Biogen, Celgene, Gilead Sciences, Johnson & Johnson, Merck, Novartis, Pfizer, and Roche. These companies are involved in the development, production, and marketing of biologic drugs. Show Less Read more